Stay updated with breaking news from Dose Escalation Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, November 02, 2023--Schrödinger today announced that new data on SGR-1505, its MALT1 inhibitor, and SGR-2921, its CDC7 inhibitor, will be presented at ASH.
FinancialContent fully hosted finance channel
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim...
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present...